The Intersections of HIV and COVID-19 in Real-Time

As the COVID-19 pandemic rages on across the world, the latest crisis is markedly reminiscent of the early days of HIV. And while the HIV epidemic is far from over, unrelenting activism, strong community engagement, partnerships and innovation are to thank for the strides the field has made towards controlling the epidemic.

Now, the response to COVID-19 is drawing heavily from these successes, and at the same time, forcing even more innovation on the HIV front.

In this episode of Px Pulse, we’ve compiled excerpts from two April webinars that offer unique perspectives on how COVID-19 and HIV are shaping one another. First, Mark Feinberg, CEO of IAVI, and Helen Rees, Executive Director of the Wits Reproductive Health and HIV Institute (Wits RHI), speak to COVID-19 vaccine development, and the role of the Coalition for Epidemic Preparedness Innovation (CEPI) in spurring vaccine funding and collaboration. We then turn to community engagement experts Sinead Delany-Moretlwe, Director of Research at Wits RHI, Vincent Basajja of the Uganda Virus Research Institute, Jau Nanyondo from Uganda’s Makerere University Walter Reed Project and Philister Adhiambo from the Kenya Medical Research Institute, who explain how HIV prevention trials are adapting in the wake of COVID-19.

Listen

Advocates Call for Ethical Research for COVID-19 Solutions

More than 260 organizations and individuals have joined an Advocates Call for Ethical Research for COVID-19 Solutions. Read the letter reiterating the essential role of ethical research, and the need to move forward based on facts and evidence, and help us carry this message forward!

GPP Overview PowerPoint

The GPP Overview PowerPoint contains 35 slides that users can draw from when introducing the Good Participatory Practice guidelines.  The PowerPoint contains slides on the history and content of the guidelines, who the intended user is,  the role and importance of GPP in the field and strategies for effective use. The slide deck is broken into sections allowing slides can be rearranged or deleted to make a complete presentation.  

Good Participatory Practice: Guidelines for TB Drug Trials

The Good Participatory Practice (GPP) guidelines for TB Drug Trials is the product of a collaboration between AVAC and the Stakeholder and Community Engagement Workgroup of the Critical Path to TB Drug Regimens. The guidelines offer trial funders, sponsors, and implementers systematic guidance on how to engage stakeholders throughout the research lifecycle. This first edition, published in 2012, contains five sections that provide context, foundational principles, and key practices for conducting TB drug trials.  

Capitalizing on Scientific Progress: Investment in HIV Prevention R&D in 2010

This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. The 2011 report describes the funding environment in the wake of a number of the findings of efficacy in the RV144, CAPRISA, iPrEx and HPTN 025 trials and calls for sustained funding to build on these results.